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Abstract
The various production routes of the prospective medical radioisotopes 43Sc, 44gSc, 44mSc, 47Sc, 
44Ti/44gSc, 99mTc, 72Se/72As and 211At were investigated by a team from the Heavy Ion Laboratory, 
University of Warsaw (HIL-UW), the University of Silesia (US) and the National Centre for 
Nuclear Research (NCNR). Three cyclotrons were employed: the K=160 heavy-ion cyclotron with 
an internal 32 MeV alpha particle beam and the p/d PETtrace medical cyclotron at HIL and the C30 
proton cyclotron at NCNR in Świerk, near Warsaw. The Thick Target Yields, activity at the End of 
Bombardment (EOB) and the impurities produced in addition to the main isotope are reported. The 
possible medical applications of these radioisotopes are briefly discussed.
Introduction
In 2012 a new unit, the Radiopharmaceuticals Production and Research Centre (RPRC) [1-4], 
devoted to the production of and research into innovative radioisotopes for medical diagnostics and 
therapy, was inaugurated at the Heavy Ion Laboratory of the University of Warsaw (HIL-UW). The 
unit is equipped with a PETtrace medical cyclotron (produced by the General Electric Company) 
providing proton and deuteron beams of 16.5 MeV and 8.4 MeV respectively. A range of chemical 
equipment for the synthesis and quality control of radiopharmaceuticals is also installed. In addition 
to the regular production of FDG for commercial use in Positron Emission Tomography the new 
unit enabled the laboratory team to enter a new research field in the applications of radioisotopes in 
medical diagnosis and therapy.
In parallel the K=160 heavy ion cyclotron [5], already in operation for almost two decades 
for basic research in nuclear physics and heavy ion applications, is employed to produce research 
quantities of medically interesting radioisotopes. In this work samples are irradiated by the internal 
alpha particle beam.
Additionally, the home made C30 cyclotron [6,7] operating at the National Centre for Nuclear 
Research in Świerk, near Warsaw, although with relatively low beam current, enables us to extend 
the available proton energy range up to 28 MeV. A proton beam with similar energy but with higher 
intensity will be available soon from a new machine accelerating protons, deuterons and alpha 
particles, currently under construction at Świerk.
The Heavy Ion Laboratory of the University of Warsaw
The Heavy Ion Laboratory (Figure 1) is a “User Facility” with around 100 national and foreign 
users per year. The isochronous Kmax=160 cyclotron (Figure 2) delivers around 3000 h of gaseous 
or metallic heavy ion beams per year with energies between 2 MeV/nucleon and 10 MeV/nucleon 
and masses up to 40. The current HIL research programme comprises nuclear physics, atomic 
physics, materials science, solid state physics, biology, particle detector development and testing, 
and recently production of research quantities of medical radioisotopes. The last mentioned subject 
is discussed in the present paper.
A second proton-deuteron cyclotron (Figure 3) is devoted to the commercial production of 
radiopharmaceuticals for Positron Emission Tomography (PET) and research into innovative 
medical radioisotopes.
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The convenient position of the HIL at the heart of the Scientific 
Campus Ochota where the scientific departments of the University 
of Warsaw, the Polish Academy of Sciences and Warsaw Medical 
University are located opens up possibilities for large interdisciplinary 
collaborations. The Institute of Nuclear Chemistry and Technology, 
located about 15 km from HIL, is also closely involved in the research 
Figure 1: The Heavy Ion Laboratory building, North side.
Figure 2: The K=160 heavy ion cyclotron, accelerating gaseous and metallic 
ions with masses up to 40 and energies up to about 10 MeV/nucleon.
Figure 3: The layout of the University of Warsaw Heavy Ion Laboratory ground 
floor. The lower part of the figure shows the heavy ion cyclotron, its beam lines 
and six nuclear physics experimental stations. The Radiopharmaceuticals 
Production and Research Centre, (placed 6 m underground) is in the upper 
part of the figure.
Figure 4: The layout of the Radiopharmaceuticals Production and Research 
Centre. The radioisotopes produced by the proton or deuteron beam from the 
PETtrace cyclotron (left of the figure) are transferred to one of the chemistry 
laboratories: L1 serving for the routine production of Fluoro-Deoxy-Glucose 
(FDG) or L2 devoted to research activity with 11C, 15O or 18F radioisotopes. 
The quality control area (right of the figure) is also divided into two parts: for 
testing regularly produced FDG and for radiopharmaceuticals in the research 
stage.
Figure 5: The PETtrace p/d cyclotron installed in its cave. 
Figure 6: Hot cells in the research laboratory.
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part of this project.
Radiopharmaceuticals Production and 
Research Centre
A 3D representation of the layout of the RPRC is given in Figure 
4. The PETtrace cyclotron and one of the chemistry rooms are shown 
in Figure 5 and 6. An external beam line for the irradiation of solid 
samples was recently designed and constructed [8] in the laboratory 
and is presented in Figure 7. The specially developed cooling system 
allows rather high proton and deuteron beam intensities to be used 
for the irradiation of these samples.
Characteristics of Proton, Deuteron and 
Alpha Particle Production Routes of the 
Investigated Radioisotopes
Tables 1-3 present the investigated radioisotopes and some 
characteristics of the production routes employed for the three 
projectiles. All our experimental data presented in these tables 
and obtained with carbonate, chloride or oxide targets (with the 
exception of metallic and natural ones) are recalculated to the highest 
commercially available target isotope enrichment. Short comments 
on a few of them are given below.
"43Sc. This radioisotope [9,10], with prospective Positron Emission 
Tomography (PET) applications, has a substantially longer half-life 
(T1/2=3.89 h) than the currently employed 18F (T1/2=1.8 h) or 68Ga 
(T1/2=68 min) and a strong β+ branch. It can, therefore, be delivered to 
hospital PET scanners from much more distant production centers. 
43Sc is also an ideal theranostic partner for the therapeutic 47Sc. We 
produced 43Sc using four different nuclear reactions: (p,n), (d,n) 
and (α,p)+(α,n). The latter reactions produce very pure 43Sc using a 
natural Ca target and are therefore preferred for centre’s equipped 
with cyclotrons accelerating alpha particle beams to energies of 20 
MeV or higher. The (d,n) route also gives a rather pure product, but 
with the currently employed medical accelerators the thick target 
efficiency for this reaction is rather low (it would be about a factor 
of two higher with 15 MeV deuterons). Finally, the (p,n) reaction has 
a good yield using medical accelerators but the resulting product is 
contaminated with 44Sc.
44Sc. A second Sc radioisotope [11,12] of a similar half-life 
(T1/2=3.97 h) to 43Sc with a strong positron branch. It decays almost 
completely to an excited state at 1157 keV. Also, an isomeric state 
of 271 keV above the ground state has a half-life of 2.4 d and decays 
to the ground state. These two properties of 44Sc allow applications 
of this radioisotope to be extended to more sophisticated uses 
besides its classic use in PET techniques. Firstly, it was proposed a 
few years ago [13] to develop a new technique, the so called-three 
photon PET, in which the high energy gamma ray in coincidence 
with the two 511 keV annihilation quanta substantially improves 
the PET spatial resolution, caused by the non-negligible range of 
the annihilating positrons (the 1157 keV gamma line is emitted 
from the place where the radiopharmaceutical is absorbed). It was 
also shown [14] that this technique substantially decreases the PET 
patient dose. Secondly, the other particularity of 44Sc, the existence of 
a much longer lived isomeric state, led to a proposal [15-17] for the 
synthesis of an in vivo 44mSc/44gSc generator for PET studies of long 
biological processes. In the present study two isomers of 44Sc were 
produced by the (p,n) and (α,np+pn+d) reactions on CaCO3 targets. 
The proton induced reaction gives a very high activity at EOB for the 
Figure 7: The external beam line installed on the PETtrace cyclotron for the 
irradiation of solid samples.
Isotope and T1/2
Projectile energy 
(MeV) Target TTY / TY (MBq/µAh)
Activity after 4 h irradiation with 1 µA beam
Reference
AEOB (MBq) Largest impurity (%)
99mTc, 6 h 16-8, 26-8 100Mo (99.815%) 404 (21), 910 (30) 1294 (67), 2914 (96) 1.26 (8) 
100Tc, 1.82 (7) 100Tc [30]
43Sc, 3.89 h 17-4 43CaCO3 (90%) 320 (20) 930 (70) 11.0 (1.0) 
44gSc [18]
44gSc, 3.97 h 12-4 44CaCO3 (94.8%) 350 (50) 10.0 (1.4) E+2 0.42 (8) 
44mSc [18]
44mSc/44gSc, 2.4 d 12-4 44CaCO3 (94.8%) 1.08 (13) 4.2 (5) 2.7 (4) 
48Sc, apart from 44gSc [18]
44gSc, 3.97 h 16-4 44CaCO3 (94.8%) 670 (80) 1.9 (2) E+3 0.66 (13) 
44mSc [18]
44mSc/44gSc, 2.4 d 16-4 44CaCO3 (94.8%) 3.2 (5) 13 (2) 1.3 (3) 
48Sc, apart from 44gSc [18]
44gSc, 3.97 h 22-6 44CaCO3 (94.8%) 870 (80) 2.5 (2) E+3 11.5 (1.4) 
43Sc [18]
44mSc/44gSc, 2.4 d 22-6 44CaCO3 (94.8%) 7.3 (6) 28 (2)
10.0 (1.2) E+2 43Sc, apart 
from 44gSc [18]
47Sc, 3.35 d 16-10 48CaCO3 (97.1%) 21 (2) 83 (8) 150 (20) 
48Sc [18]
47Sc, 3.35 d 22-17 48CaCO3 (97.1%) 49 (4) 193 (12) 35 (4) 
48Sc [18]
47Sc, 3.35 d 28-16 48CaCO3 (97.1%) 85 (5) 334 (16) 27 (2) 
48Sc [18]
47Sc, 3.35 d 28-18 48TiO2 (99.6%) 2.0 (1) 7.7 (3)
20.0 (1.1) E+2 44gSc, 57 (3) 
44mSc [18]
Table 1: The prospective medical radioisotopes investigated using a proton beam. The column TTY/TY denotes the Thick Target Yield or Target Yield in MBq/µAh.
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ground state formation and a more than 150 times lower one for the 
isomer after 4 h of the irradiation with 16 MeV protons. The isomer/
ground state activity ratio at EOB substantially increases for the alpha 
particle route. However, due to the much larger range of protons than 
alpha particles in the CaCO3 target, the isomer activity is only 1.5 
lower than the ground state one for protons than for alpha particles 
of the same beam intensity and for the appropriate beam energies. 
Evidently, due to much larger 44gSc production a much longer cooling 
time is necessary for proton irradiation in order to obtain a pure 
44mSc. All these aspects should be considered if an in vivo generator is 
to be synthesized [18].
47Sc. This therapeutic radioisotope, with a low energy β-decay, is 
the theranostic partner of Sc positron emitters and was previously 
produced using slow or fast neutrons from nuclear reactors [19-21]. 
The alternative accelerator routes are currently being investigated 
in a number of research centre’s under the Cooperative Research 
Programme of the IAEA [22]. The (p,2n) reaction for the formation 
of this isotope was recently proposed [10,22] and was investigated in 
detail by our group [18]. It was shown that only a rather limited proton 
energy range can be used to produce relatively pure 47Sc and even 
then a long cooling time of the irradiated sample is necessary to avoid 
the presence of 48Sc, a radioisotope emitting a few high energy gamma 
lines, strongly increasing the patient dose (for 10 hours irradiation 
time, 150 hours after EOB the 48Sc activity is 10% of the 47Sc one and 
420 hours are necessary to reach 1% contamination). Assuming that 
an activity of 2 GBq of 47Sc is necessary for one therapeutic application, 
that the irradiation time is 10 hours and that the proton beam current 
is 100 µA, one irradiation leads to one patient application containing 
1% contamination of the injected sample with 48Sc.
The (p,2p) reaction on the rather cheap 48Ti oxide was also 
investigated [18]. The reaction yield obtained at 28 MeV to 18 MeV 
Isotope and T1/2 Projectile energy (MeV) Target TTY (MBq/µAh)
Activity after 4 h irradiation with 1 µA beam
Reference
AEOB (MBq) Largest impurity (%)
43Sc, 3.89 h 7-0 42CaCO3 (95.9%) 35 (2) 99 (7) 0.22 (3) 
44gSc [18]
Table 2: The prospective medical radioisotopes investigated using a deuteron beam. The column TTY denotes the Thick Target Yield in MBq/µAh.
Isotope and T1/2 Projectile energy (MeV) Target TTY / TY (MBq/µAh)
Activity after 4 h irradiation with 1 µA beam
Reference
AEOB (MBq) Largest impurity (%) at EOB
211At, 7.2 h 29-19 natBi 37 (6) 123 (20) 0.025 (6) 210At [29]
72As, 26 h 29-16 70GeO2 (95.3%) 11.7 (9) 44 (3) 220 (10) 
73gSc
72Se/72As, 8.5 d 29-16 70GeO2 (95.3%) 0.84 (0.14) 3.3 (6) 2950 (40) 
73gSe
43Sc, 3.89 h 20-0 natCaCO3 84 (4) 240 (11) 0.034 (5) 
47Sc [31]
43Sc, 3.89 h 20-0 natCa (metal) 210 (30) 600 (86) 0.035 (7) 47Sc [31]
43Sc, 3.89 h 20-0 40CaCO3 (99.99%) 88 (13) 252 (37) 2.5 (1) E-4 
47Sc [31]
43Sc, 3.89 h 31-0 natCaO 98 (10) 280 (28) 0.75 (9) 44gSc [29]
43Sc, 3.89 h 29-19 41KCl (95.4%) 60 (9) 172 (26) 13 (1) 44gSc [31]
44gSc, 3.97 h 29-12 42CaCO3 (95.9%) 44 (7) 127 (20) 13.7 (8) 
44mSc [31]
44mSc/44gSc, 2.4 d 29-12 42CaCO3 (95.9%) 4.7 (8) 18 (3) 40.6 (9) 
43Sc, apart from 44gSc [31]
44gSc, 3.97 h 20-2 41KCl (95.4%) 61 (10) 176 (29) 15.9 (7) 43Sc [31]
44mSc/44gSc, 2.4 d 20-2 41KCl (95.4%) 3.0 (6) 12 (2) 233 (15) 43Sc, apart from 44gSc [31]
47Sc, 3.35 d 20-0 44CaCO3 (99.2%) 1.0 (1) 3.7 (4) 51 (3) 
43Sc [18]
44Ti/44Sc, 60 y 29-12 42CaCO3 (95.9%) 3.2 (8) E-5 1.3 (3) E-4 70 (20) 
46Sc *
Table 3: The prospective medical radioisotopes investigated using an alpha particle beam. The column TTY/TY denotes the Thick Target Yield or Target Yield in 
MBq/µAh.
*for this very long-lived radioisotope the impurity at 1 y after EOB is indicated.
was, however, 12 times smaller than with the (p,2n) reaction and a 
substantial cooling time was also necessary.
44Ti/44gSc. This 60 y half-life generator was previously produced 
by the Mainz team [23] using a 200 mA proton beam at 25 MeV on 
a thick 45Sc target. As the half-life of the mother isotope is very long, 
the irradiation time was 200 days in order to obtain 185 MBq of 44Ti 
activity. We have produced this isotope by the (α,2n) reaction on a 
thick 42Ca target using a 29 MeV alpha particle beam. In Table 3, we 
present the TTY of 44Ti production for an alpha particle beam within 
the investigated energy range. However, a substantial cross section 
for this reaction extends up to much higher energies. Therefore, 
using JANIS library, we also calculated the TTY value for the energy 
range 56 MeV to 12 MeV, the upper energy value corresponding 
to the expected alpha particle energy of the future high current 
SPIRAL2 linear accelerator [24]. The value obtained was 76 MBq/
μAh. Assuming e.g. the future SPIRAL2 alpha particle beam intensity 
to be 3.6 pmA the production of 44Ti/44gSc with equivalent strength 
to the Mainz generator would need about 20 days of irradiation 
time of maximum enriched, commercially available target material. 
Evidently, the question of whether the target can sustain such a high 
current should be resolved first.
211At. This prospective therapeutic alpha emitter has been studied 
at a number of places around the world [25-27]. The main problem 
encountered is the stability of the injected radiopharmaceuticals. 
Within our programme this radioisotope was and is currently 
produced by irradiation of a natural, mono-isotopic Bi target with 
a He+ internal cyclotron beam [28,29]. The various ways of forming 
radiopharmaceuticals with it are being studied by our collaborators 
from the Institute of Nuclear Chemistry and Technology in Warsaw. 
The production efficiency as a function of the He+ bombarding 
energy and the level of contamination by the very dangerous 210At 
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was determined [29].
Summary and Conclusions
Research into the production of prospective medical radioisotopes 
conducted at the Heavy Ion Laboratory of the University of Warsaw 
was begun a few years ago and is being actively pursued. In this paper 
a list of the targets and nuclear reactions investigated up to the present 
time was presented. Research on the synthesis of radiopharmaceuticals 
is performed at the Institute of Nuclear Chemistry and Technology 
in Warsaw and the POLATOM Department of the National Centre 
for Nuclear Research in Świerk, near Warsaw using the radioisotopes 
thus produced. The location of HIL in the Warsaw University 
scientific campus opens possibilities for large-scale interdisciplinary 
activity using the produced medical radioisotopes.
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